MABE354 Sigma-AldrichAnti-Uracil-DNA glycosylase Antibody, clone 8G10.1
Anti-Uracil-DNA glycosylase Antibody, clone 8G10.1, Cat. No. MABE354, is a highly specific mouse monoclonal antibody, that targets UNG and has been tested in Western Blotting and Immunohistochemistry.
More>> Anti-Uracil-DNA glycosylase Antibody, clone 8G10.1, Cat. No. MABE354, is a highly specific mouse monoclonal antibody, that targets UNG and has been tested in Western Blotting and Immunohistochemistry. Less<<Recommended Products
Overview
| Replacement Information | 
|---|
Key Spec Table
| Species Reactivity | Key Applications | Host | Format | Antibody Type | 
|---|---|---|---|---|
| H | WB, IHC | M | Purified | Monoclonal Antibody | 
| References | 
|---|
| Product Information | |
|---|---|
| Format | Purified | 
| Presentation | Purified mouse monoclonal IgG2aκ antibody in buffer containing 0.1 M Tris-Glycine (pH 7.4), 150 mM NaCl with 0.05% sodium azide. | 
| Quality Level | MQ100 | 
| Physicochemical Information | 
|---|
| Dimensions | 
|---|
| Materials Information | 
|---|
| Toxicological Information | 
|---|
| Safety Information according to GHS | 
|---|
| Safety Information | 
|---|
| Storage and Shipping Information | |
|---|---|
| Storage Conditions | Stable for 1 year at 2-8°C from date of receipt. | 
| Packaging Information | |
|---|---|
| Material Size | 100 μg | 
| Transport Information | 
|---|
| Supplemental Information | 
|---|
| Specifications | 
|---|
| Global Trade Item Number | |
|---|---|
| Catalogue Number | GTIN | 
| MABE354 | 04055977176902 | 
Documentation
Anti-Uracil-DNA glycosylase Antibody, clone 8G10.1 SDS
| Title | 
|---|
Anti-Uracil-DNA glycosylase Antibody, clone 8G10.1 Certificates of Analysis
| Title | Lot Number | 
|---|---|
| Anti-Uracil-DNA glycosylase, -Q2583339 | Q2583339 | 
| Anti-Uracil-DNA glycosylase, clone 8G10.1 - 3587089 | 3587089 | 
Technical Info
| Title | 
|---|
| Characterization of Estrogen Receptor α Phosphorylation Sites in Breast Cancer Tissue Using the SNAP i.d® 2.0 System | 
| White Paper: Further considerations of antibody validation and usage. | 

 


 
  

 

 
